Article
Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 1 Dec 2016
Grebely Jason, Mauss Stefan, Brown Ashley, Bronowicki Jean-Pierre, Puoti Massimo, Wyles David, Natha Macky, Zhu Yanni, Yang Junming, Kreter Bruce, Brainard Diana M, Yun Chohee, Carr Val, Dore Gregory J
Abstract excerpt
BACKGROUND: Interferon-based hepatitis C virus (HCV) therapy is safe and effective among people receiving opioid substitution therapy (OST), but treatment uptake remains low. Our aim was to evaluate the impact of OST and drug use during therapy on completion, adherence, sustained virologic response (SVR12), and safety of ledipasvir/sofosbuvir ± ribavirin. METHODS: The phase 3 ION studies evaluated a fixed-dose...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.